Scarica l'app Stockscreener
0.4511
8.22%
-0.0404
Dopo l'orario di chiusura:
.46
0.0089
+1.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$0.4915
Aprire:
$0.483
Volume 24 ore:
1.58M
Relative Volume:
0.50
Capitalizzazione di mercato:
$66.03M
Reddito:
$15.93M
Utile/perdita netta:
$-64.59M
Rapporto P/E:
-0.6015
EPS:
-0.75
Flusso di cassa netto:
$-59.50M
1 W Prestazione:
-14.60%
1M Prestazione:
-14.16%
6M Prestazione:
-45.39%
1 anno Prestazione:
-29.63%
Intervallo 1D:
$0.451
$0.4976
Intervallo di 1 settimana:
$0.451
$0.54
Portata 52W:
$0.451
$1.92
Veru Inc Stock (VERU) Company Profile
Nome
Veru Inc
Settore
Industria
Telefono
(312) 595-9123
Indirizzo
2916 N. MIAMI AVENUE, MIAMI, FL
Confronta VERU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
0.4511 | 66.03M | 15.93M | -64.59M | -59.50M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-14 | Iniziato | B. Riley Securities | Buy |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2023-06-07 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-04-13 | Iniziato | Jefferies | Buy |
| 2021-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-20 | Iniziato | Oppenheimer | Outperform |
| 2018-07-03 | Iniziato | Maxim Group | Buy |
Mostra tutto
Veru Inc Borsa (VERU) Ultime notizie
VERU stock touches 52-week low at $0.47 amid market challenges - Investing.com
Here's Why Veru (VERU) Looks Ripe for Bottom Fishing - Yahoo Finance
Oppenheimer & Co. Inc. Boosts Stake in Veru Inc. (NASDAQ:VERU) - MarketBeat
B. Riley Cuts Price Target on Veru to $2 From $5, Keeps Buy Rating -March 07, 2025 at 07:49 am EST - Marketscreener.com
Veru Inc to Host Earnings Call - ACCESS Newswire
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround - Yahoo Finance
VERU stock touches 52-week low at $0.49 amid market challenges - Investing.com Canada
Veru, Inc. to Host Earnings Call - ACCESS Newswire
Veru Inc. (NASDAQ:VERU) Director Acquires $52,403.45 in Stock - MarketBeat
Director Makes Bold Move with Major Veru Stock Purchase! - TipRanks
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action - ACCESS Newswire
3 US Penny Stocks With Market Caps Under $300M To Consider - Simply Wall St
Veru Inc. director Michael Rankowitz buys $84,350 in common stock - Investing.com
Veru Inc. director Michael Rankowitz buys $84,350 in common stock By Investing.com - Investing.com South Africa
Short Interest in Veru Inc. (NASDAQ:VERU) Rises By 14.3% - MarketBeat
Veru (NASDAQ:VERU) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Veru (NASDAQ:VERU) Issues Earnings Results - MarketBeat
Veru Inc. Reports Fiscal 2025 First Quarter Financial Results and Clinical Program ProgressVERU INC. (NASDAQ: VERU) recently released its financial results for the first quarter of fiscal 2025, along with key updates on its clinical development progr - Defense World
Earnings call transcript: Veru Inc Q1 2025 beats EPS forecast, stock dips - MSN
Veru Inc. (NASDAQ:VERU) Short Interest Up 14.3% in January - Defense World
Oppenheimer Adjusts Price Target on Veru to $4 From $5, Keeps Outperform Rating - Marketscreener.com
Veru Inc. (NASDAQ:VERU) Q1 2025 Earnings Call Transcript - Insider Monkey
Veru Inc Faces Uncertain Financial Future Amidst Lack of Revenue and Regulatory Hurdles - TipRanks
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ... - Yahoo Finance
Veru Inc. Reports Strong Q1 Results and Clinical Progress - TipRanks
Veru Inc Earnings Call: Clinical Wins Amid Financial Concerns - TipRanks
Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment - MSN
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress - GlobeNewswire
VERU INC. SEC 10-Q Report - TradingView
Veru Inc Reports Q1 EPS of -$0.01, Beating Estimates; Revenue Ma - GuruFocus.com
Earnings call transcript: Veru Inc Q1 2025 beats EPS forecast, stock dips By Investing.com - Investing.com South Africa
Veru Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Veru Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your RightsVERU - Newsfile
Veru Inc. Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress - TradingView
Veru reports Q1 cont-op EPS (1c) vs. (8c) last year - TipRanks
Veru Inc. Reports Positive Phase 2b QUALITY Study Results and Announces New Indication for Sabizabulin in Atherosclerotic Coronary Artery Disease - Nasdaq
Game-Changing Clinical Results: Veru's Drug Outperforms Weight Loss Giant Wegovy in Muscle Protection - StockTitan
Veru Inc. (NASDAQ:VERU) Stock Position Boosted by SG Americas Securities LLC - Defense World
Veru Inc (VERU) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus.com
Nine Energy Service Inc Inc. (NINE) Price Performance Over the Years: A Comparative Study - The InvestChronicle
Trading Day Review: Veru Inc (VERU) Loses Momentum, Closing at 0.56 - The Dwinnex
Veru Inc Azioni (VERU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):